ESSA’s primary research efforts are focused on developing small molecule therapies to treat patients with prostate cancer. Our lead candidate, EPI-7386, is a highly-selective, oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). We believe that our approach is highly differentiated and has the potential to bypass current androgen receptor-based resistance mechanisms that develop in patients with castration resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (mCRPC).